Genenta Science S.p.A. Stock (NASDAQ:GNTA)
Previous Close
$4.00
52W Range
$2.20 - $5.87
50D Avg
$4.07
200D Avg
$3.95
Market Cap
$71.96M
Avg Vol (3M)
$12.83K
Beta
0.77
Div Yield
-
GNTA Company Profile
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
GNTA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CYT | Cyteir Therapeutics, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| CSBR | Champions Oncology, Inc. |
| JANX | Janux Therapeutics, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| PHVS | Pharvaris N.V. |
| RZLT | Rezolute, Inc. |
| PEPG | PepGen Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| MOLN | Molecular Partners AG |
| PRDS | Pardes Biosciences, Inc. |
| OPT | Opthea Limited |
| ELYM | Eliem Therapeutics, Inc. |